BACKGROUND: A lower dosage of tyrosine kinase inhibitors (TKIs) in patients with chronic myeloid leukaemia (CML) has shown efficacy in managing short-term toxicity and maintaining a deep molecular response in patients who fail to achieve treatment-free remission. METHOD: From over 700 patients with CML who were treated at two centres over the last three decades, this retrospective study identified eight patients characterised by long-term treatment failure and simultaneous prolonged significant haematologic toxicity that prevented the use of the standard tyrosine kinase inhibitor dosage. RESULTS: Patients had a high or intermediate ELTS risk score, and most had significant comorbidities. Two patients were treated previously with busulfan, and four were aged over 70, which might explain the reduced pool of normal haematopoietic stem cells. However, concomitant myelodysplastic syndrome or the presence of clonal haematopoiesis of indeterminate potential was not demonstrated. Despite prolonged treatment failure, the survival of these patients (who were ineligible for stem cell transplantation) ranged from 45-396 months. Neither mutations in the ABL kinase domain nor additional cytogenetic abnormalities developed during the treatment of these patients, prompting speculation about the low selective pressure of low-dose tyrosine kinase inhibitors and/or the absence of mutations at diagnosis. CONCLUSION: It is important not to stop treatment with tyrosine kinase inhibitors at a low personalised dosage in CML patients with prolonged significant haematologic toxicity despite long-term treatment failure.

Institute of Hematology and Blood Transfusion Prague Czech Republic

University Hospital Olomouc Faculty of Medicine and Dentistry Palacky University in Olomouc Czech Republic

See more in PubMed

Hochhaus A., Baccarani M., Silver R.T., Schiffer C., Apperley J.F., Cervantes F., Clark R.E., Cortes J.E., Deininger M.W., Guilhot F., Hjorth-Hansen H., Hughes T.P., Janssen J.J.W.M., Kantarjian H.M., Kim D.W., Larson R.A., Lipton J.H., Mahon F.X., Mayer J., Nicolini F., Niederwieser D., Pane F., Radich J.P., Rea D., Hehlmann R. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020;34:966–984. doi: 10.1038/s41375-020-0776-2. PubMed DOI PMC

Shah N.P., Rousselot P., Schiffer C., Rea D., Cortes J.E., Milone J., Mohamed H., Healey D., Kantarjian H., Hochhaus A., Saglio G. Dasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180-034. Am J Hematol. 2016;91:869–874. doi: 10.1002/ajh.24423. PubMed DOI PMC

Hochhaus A., Saglio G., Hughes T.P., Larson R.A., Kim D.W., Issaragrisil S., le Coutre P.D., Etienne G., Dorlhiac-Llacer P.E., Clark R.E., Flinn I.W., Nakamae H., Donohue B., Deng W., Dalal D., Menssen H.D., Kantarjian H.M. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia. 2016;30:1044–1054. doi: 10.1038/leu.2016.5. PubMed DOI PMC

Cortes J.E., Gambacorti-Passerini C., Deininger M.W., Mauro M.J., Chuah C., Kim D.W., Dyagil I., Glushko N., Milojkovic D., le Coutre P., Garcia-Gutierrez V., Reilly L., Jeynes-Ellis A., Leip E., Bardy-Bouxin N., Hochhaus A., Brümmendorf T.H. Bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia: results from the randomized BFORE trial. J Clin Oncol. 2018;36:231–237. doi: 10.1200/JCO.2017.74.7162. PubMed DOI PMC

Cortes J., Apperley J., Lomaia E., Moiraghi B., Sutton M.U., Pavlovsky C., Chuah C., Sacha T., Lipton J.H., Schiffer C.A., McCloskey J., Hochhaus A., Rousselot P., Rosti G., de Lavallade H., Turkina A., Rojas C., Arthur C.K., Maness L., Talpaz M., Mauro M., Hall T., Lu V., Srivastava S., Deininger M. Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial. Blood. 2021;138:2042–2050. doi: 10.1182/blood.2021012082. PubMed DOI PMC

Steegmann J.L., Baccarani M., Breccia M., Casado L.F., Garcia-Gutierrez V., Hochhaus A., Kim D.W., Kim T.D., Khoury H.J., Le Coutre P., Mayer J., Milojkovic D., Porkka K., Rea D., Rosti G., Saussele S., Hehlmann R., Clark R.E. European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia. Leukemia. 2016;30:1648–1671. doi: 10.1038/leu.2016.104. PubMed DOI PMC

Faber E., Nausová J., Jarosová M., Egorin M.J., Holzerová M., Rozmanová S., Maresová I., Divoký V., Indrák K. Intermittent dosage of imatinib mesylate in CML patients with a history of significant hematologic toxicity after standard dosing. Leuk Lymphoma. 2006;47:1082–1090. doi: 10.1080/10428190600565057. PubMed DOI

Faber E., Divoká M., Skoumalová I., Novák M., Marešová I., Mičová K., Friedecký D., Adam T., Jarošová M., Indrák K. A lower dosage of imatinib is sufficient to maintain undetectable disease in patients with chronic myeloid leukemia with long-term low-grade toxicity of the treatment. Leuk Lymphoma. 2016;57:370–375. doi: 10.3109/10428194.2015.1056184. PubMed DOI

Carella A.M., Lerma E. Durable responses in chronic myeloid leukemia patients maintained with lower doses of imatinib mesylate after achieving molecular remission. Ann Hematol. 2007;86:749–752. doi: 10.1007/s00277-007-0326-2. PubMed DOI

Russo D., Martinelli G., Malagola M., Skert C., Soverini S., Iacobucci I., de Vivo A., Testoni N., Castagnetti F., Gugliotta G., Turri D., Bergamaschi M., Pregno P., Pungolino E., Stagno F., Breccia M., Martino B., Intermesoli T., Fava C., Abruzzese E., Tiribelli M., Bigazzi C., Cesana B.M., Rosti G., Baccarani M. Effects and outcome of a policy of intermittent imatinib treatment in elderly patients with chronic myeloid leukemia. Blood. 2013;121:5138–5144. doi: 10.1182/blood-2013-01-480194. PubMed DOI

Michel C., Burchert A., Hochhaus A., Saussele S., Neubauer A., Lauseker M., Krause S.W., Kolb H.J., Hossfeld D.K., Nerl C., Baerlocher G.M., Heim D., Brümmendorf T.H., Fabarius A., Haferlach C., Schlegelberger B., Balleisen L., Goebeler M.E., Hänel M., Ho A., Dengler J., Falge C., Möhle R., Kremers S., Kneba M., Stegelmann F., Köhne C.H., Lindemann H.W., Waller C.F., Spiekermann K., Berdel W.E., Müller L., Edinger M., Mayer J., Beelen D.W., Bentz M., Link H., Hertenstein B., Fuchs R., Wernli M., Schlegel F., Schlag R., de Wit M., Trümper L., Hebart H., Hahn M., Thomalla J., Scheid C., Schafhausen P., Verbeek W., Eckart M.J., Gassmann W., Schenk M., Brossart P., Wündisch T., Geer T., Bildat S., Schäfer E., Hasford J., Hehlmann R., Pfirrmann M. Imatinib dose reduction in major molecular response of chronic myeloid leukemia: results from the German Chronic Myeloid Leukemia-Study IV. Haematologica. 2018;104:955–962. doi: 10.3324/haematol.2018.206797. PubMed DOI PMC

Cervantes F., Correa J.G., Perez I., Garcia-Gutierrez V., Redondo S., Colomer D., Jiménez-Velasco A., Steegmann J.L., Sánchez-Guijo F., Ferrer-Marín F., Pereira A., Osorio S. Imatinib dose reduction in patients with chronic myeloid leukemia in sustained deep molecular response. Ann Hematol. 2017;96:81–85. doi: 10.1007/s00277-016-2839-z. PubMed DOI

Itamura H., Kubota Y., Shindo T., Ando T., Kojima K., Kimura S. Elderly patients with chronic myeloid leukemia benefit from a dasatinib dose as low as 20 mg. Clin Lymphoma Myeloma Leuk. 2017;17:370–374. doi: 10.1016/j.clml.2017.02.023. PubMed DOI

Baccarani M., Saglio G., Goldman J., Hochhaus A., Simonsson B., Appelbaum F., Apperley J., Cervantes F., Cortes J., Deininger M., Gratwohl A., Guilhot F., Horowitz M., Hughes T., Kantarjian H., Larson R., Niederwieser D., Silver R., Hehlmann R. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood. 2006;108:1809–1820. doi: 10.1182/blood-2006-02-005686. PubMed DOI

Baccarani M., Cortes J., Pane F., Niederwieser D., Saglio G., Apperley J., Cervantes F., Deininger M., Gratwohl A., Guilhot F., Hochhaus A., Horowitz M., Hughes T., Kantarjian H., Larson R., Radich J., Simonsson B., Silver R.T., Goldman J., Hehlmann R. European LeukemiaNetChronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol. 2009;27:6041–6051. doi: 10.1200/JCO.2009.25.0779. PubMed DOI PMC

Baccarani M., Deininger M.W., Rosti G., Hochhaus A., Soverini S., Apperley J.F., Cervantes F., Clark R.E., Cortes J.E., Guilhot F., Hjorth-Hansen H., Hughes T.P., Kantarjian H.M., Kim D.W., Larson R.A., Lipton J.H., Mahon F.X., Martinelli G., Mayer J., Müller M.C., Niederwieser D., Pane F., Radich J.P., Rousselot P., Saglio G., Saußele S., Schiffer C., Silver R., Simonsson B., Steegmann J.L., Goldman J.M., Hehlmann R. European Leukemia Net recommendations for the management of chronic myeloid leukemia. Blood. 2013;122:872–884. doi: 10.1182/blood-2013-05-501569. PubMed DOI PMC

Gabert J., Beillard E., van der Velden V.H.J., Bi W., Grimwade D., Pallisgaard N., Barbany G., Cazzaniga G., Cayuela J.M., Cavé H., Pane F., Aerts J.L.E., De Micheli D., Thirion X., Pradel V., González M., Viehmann S., Malec M., Saglio G., van Dongen J.J.M. Standardization and quality control studies of „real-time“ quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for rezidual disease detection in leukemia - a Europe Against Cancer Program. Leukemia. 2003;17:2318–2357. doi: 10.1038/sj.leu.2403135. PubMed DOI

van Dongen J.J., Macintyre E.A., Gabert J.A., Delabesse E., Rossi V., Saglio G., Gottardi E., Rambaldi A., Dotti G., Griesinger F., Parreira A., Gameiro P., Diáz M.G., Malec M., Langerak A.W., San Miguel J.F., Biondi A. Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: Investigation of minimal residual disease in acute leukemia. Leukemia. 1999;13:1901–1928. doi: 10.1038/sj.leu.2401592. PubMed DOI

Common Terminology Criteria For Adverse Events (CTCAE) Version 5. Published: November 27. US Department of Health and Human Services, National Institutes of Health, National Cancer Institute. https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcae_v5_quick_reference_5x7.pdf.

Hehlmann R., Lauseker M., Saußele S., Pfirrmann M., Krause S., Kolb H.J., Neubauer A., Hossfeld D.K., Nerl C., Gratwohl A., Baerlocher G.M., Heim D., Brümmendorf T.H., Fabarius A., Haferlach C., Schlegelberger B., Müller M.C., Jeromin S., Proetel U., Kohlbrenner K., Voskanyan A., Rinaldetti S., Seifarth W., Spieß B., Balleisen L., Goebeler M.C., Hänel M., Ho A., Dengler J., Falge C., Kanz L., Kremers S., Burchert A., Kneba M., Stegelmann F., Köhne C.A., Lindemann H.W., Waller C.F., Pfreundschuh M., Spiekermann K., Berdel W.E., Müller L., Edinger M., Mayer J., Beelen D.W., Bentz M., Link H., Hertenstein B., Fuchs R., Wernli M., Schlegel F., Schlag R., de Wit M., Trümper L., Hebart H., Hahn M., Thomalla J., Scheid C., Schafhausen P., Verbeek W., Eckart M.J., Gassmann W., Pezzutto A., Schenk M., Brossart P., Geer T., Bildat S., Schäfer E., Hochhaus A., Hasford J. Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants. Leukemia. 2017;31:2398–2406. doi: 10.1038/leu.2017.253. PubMed DOI PMC

Peng B., Lloyd P., Schran H. Clinical pharmacokinetics of imatinib. Clin Pharmacokinet. 2005;44:879–894. doi: 10.2165/00003088-200544090-00001. PubMed DOI

Kusne Y., Xie Z., Patnaik M.M. Clonal hematopoiesis: molecular and clinical implications. Leukemia Res. 2022;113 doi: 10.1016/j.leukres.2022.106787. PubMed DOI

Claudiani S., Apperley J.F., Szydlo R., Khan A., Nesr G., Hayden C., Innes A.J., Dominy K., Foskett P., Foroni L., Khorashad J., Milojkovic D. TKI dose reduction can effectively maintain major molecular remission in patients with chronic myeloid leukaemia. Br J Haematol. 2021;193:346–355. doi: 10.1111/bjh.17286. PubMed DOI

Rousselot P., Johnson-Ansah H., Huguet F., Legros L., Escoffre-Barbe M., Gardembas M. Personalized daily doses of Imatinib by therapeutic drug monitoring increase the rates of molecular responses in patients with chronic myeloid leukemia. Final results of the randomized OPTIM imatinib study. Blood. 2015;126:133. doi: 10.1182/blood.V126.23.133.133. PubMed DOI

Copland M. Is there a role for does modification of TKI therapy in CML? Curr Hematol Malign Rep. 2019;14:337–345. doi: 10.1007/s11899-019-00524-w. PubMed DOI PMC

Iurlo A., Cattaneo D., Bucelli C., Breccia M. Dose optimization of tyrosine kinase inhibitors in chronic myeloid leukemia: a new therapeutic challenge. J Clin Med. 2021;10:515. doi: 10.3390/jcm10030515. PubMed DOI PMC

Fassoni A.C., Baldow C., Roeder I., Glauche I. Reduced tyrosine kinase inhibitor dose is predicted to be as effective as standard dose in chronic myeloid leukemia: a simulation study based on phase III trial data. Haematologica. 2018;103:1825–1834. doi: 10.3324/haematol.2018.194522. PubMed DOI PMC

Schmitt M.W., Pritchard J.R., Leighow S.M., Aminov B.I., Beppu L., Kim D.S., Hodgson J.G., Rivera V.M., Loeb L.A., Radich J.P. Single-molecule sequencing reveals patterns of preexisting drug resistance that suggest treatment strategies in Philadelphia-positive leukemias. Clin Cancer Res. 2018;24:5321–5334. doi: 10.1158/1078-0432.CCR-18-0167. PubMed DOI PMC

Branford S., Wang P., Yeung D.T., Thomson D., Purins A., Wadham C., Shahrin N.H., Marum J.E., Nataren N., Parker W.T., Geoghegan J., Feng J., Shanmuganathan N., Mueller M.C., Dietz C., Stangl D., Donaldson Z., Altamura H., Georgievski J., Braley J., Hughes T.P. Integrative genomic analysis reveals cancer-associated mutations at diagnosis of CML in patients with high-risk disease. Blood. 2018;132:948–961. doi: 10.1182/blood-2018-02-832253. PubMed DOI